Clinical reviewer: Dr. Sarah Boss, MD

This guide is published by COGNIFUL, part of THE BALANCE GROUP. It compares selected international medical and addiction pathways with our possible later residential role. It is not an independent ranking of equivalent luxury detox facilities. The actual accepting program, medical scope and availability must be confirmed for each person.

Drug detox is often used to describe withdrawal management, but the phrase can conceal very different clinical needs. A person may need treatment for intoxication, withdrawal, a substance use disorder, a medication concern or several overlapping conditions. The first assessment should identify which problem is being addressed. An advertised detox package does not establish that the same intervention is appropriate for every substance.

Start with an accurate account of substances and medicines, including formulations where known, actual use, recent changes and previous treatment. Include alcohol, prescribed sedatives, opioid medication and products obtained outside medical care. Explain uncertainty about a product rather than guessing. The clinical team needs the actual pattern, not only the substance the person considers their main problem.

Also describe current symptoms, medical conditions and psychiatric concerns. Previous overdose, severe withdrawal, seizures or hospital care should be disclosed. A person should not minimize these details to secure a preferred room or destination. The appropriate response may be a different medical setting, and identifying that need is a useful result of assessment.

The providers illustrate different medical and addiction-treatment roles. They are not interchangeable accommodation packages, and the table does not establish that any one accepts every substance or medical complication. Ask which exact program is proposed, what it can manage directly and what would require another service. A provider’s general detox description should be tested against the individual’s history.

COGNIFUL in Mallorca, Spain, offers detoxification as part of its addiction treatment pathway. If withdrawal care or acute medical treatment is needed, that service should be identified first. The pathway may involve a medical unit, ongoing prescribing and a separate residential program. What matters is that the stages connect with clear responsibility rather than leave gaps between them.

For opioid-related concerns, ask whether opioid use disorder has been diagnosed and how ongoing treatment will be provided. The CDC recommends medication treatment for opioid use disorder and advises against detoxification alone because of increased risks of return to use, overdose and overdose death. A program should not treat being temporarily opioid-free as the whole clinical objective. [1]

Ask how appropriate medication treatment is offered or arranged and how it continues after discharge. The responsible provider should explain the actual service rather than rely on a general statement that medication is available. If the residential program does not prescribe directly, identify the accepting clinician or service. A referral that has not been accepted is not an established treatment arrangement.

Overdose prevention should also be discussed with the appropriate clinical team. The CDC recommends naloxone and education for people with opioid use disorder and relevant household members. Ask how this is addressed within the individual’s plan and how support continues after the medical phase. These are selection questions for professional care, not instructions for self-directed detox. [1]

If opioid pain medication is involved, the original pain condition still deserves assessment. A person should not be forced to choose between discussing harmful use and having pain taken seriously. Ask who coordinates pain and addiction care, what information is needed and which responsibilities remain with existing specialists. A coherent plan addresses both the medical indication and the actual pattern of use.

Physical dependence on a prescribed benzodiazepine is distinct from a substance use disorder. The joint guideline emphasizes this because dependence can arise during regular prescribed use. The assessment should not label every person with withdrawal symptoms addicted. It should establish whether the main need is a careful medication review, addiction treatment, a higher medical setting or a combination. [2]

Abrupt benzodiazepine discontinuation or overly rapid reductions can cause severe withdrawal, including seizures. Combining benzodiazepines with opioids or alcohol can create serious additional risks. Do not stop, substitute or combine products independently to prepare for treatment. The responsible clinician should guide the medical plan and level of support. [9]

Ask how the service responds when the required process extends beyond a short admission. The joint guideline recognizes that some benzodiazepine plans are prolonged and may require continuing review. A standard drug-detox timetable should not be applied without individual assessment. The next prescriber and support arrangement should be identified before the person leaves the medical service. [2]

Stimulant intoxication and withdrawal need substance-specific assessment of physical and mental health. ASAM and AAAP guidance recognizes medical and psychiatric complications and the need for an appropriate care setting. A generic detox package designed around another substance does not demonstrate the relevant expertise. Ask how the service evaluates current symptoms and what specialist support is available. [3]

The subsequent treatment plan should address the pattern of use, the role of the substance in daily life and the person’s wider needs. Work performance, prolonged wakefulness, distress or social contexts may be relevant for some people, but the formulation should come from assessment. A residential stay should have defined therapeutic goals rather than simply offer a place to wait until acute effects change.

Ask what happens if symptoms require hospital or acute psychiatric care. A service should explain that boundary before admission. Comfort and privacy can be considered once the clinically appropriate options are known; they should not be used to infer that a residence can manage every substance-related presentation.

A person may describe one drug as the problem while also using alcohol, sedatives or prescribed pain medication. The combination can change the assessment and care setting. Ask which clinician holds the overall medical responsibility and how information from different prescribers or services is reconciled. Separate plans can leave important questions unresolved if no one has the complete picture.

Do not assume that a substance is irrelevant because it is prescribed or used only occasionally. Explain the actual pattern and let the clinician assess its significance. Where the contents of a nonprescribed product are uncertain, disclose that uncertainty. The service should explain what can be assessed and what remains unknown rather than offer reassurance based only on a familiar name.

Psychiatric and medical needs should be considered alongside substance use. If the person is acutely unwell, the selected service must be equipped for that level of care. A general claim to treat co-occurring needs is not proof of emergency capacity. Ask what is managed onsite, what is referred and how a change in condition is handled.

The outcome should be an understandable account of the problem, the recommended setting and the next steps. Ask why that level of care is appropriate, what medical treatment is proposed and what could require a different setting. A provider may need records or further assessment before answering; acknowledging that need is preferable to a premature promise about duration or outcome.

The plan should also identify what follows the medical phase. Depending on the situation, this may involve ongoing medication treatment, outpatient care, residential therapy or another specialist service. The next provider should be named and acceptance confirmed. The person should not be left to organize a new clinical network at the point of discharge.

Urgent symptoms belong with local medical services. Breathing difficulty, suspected overdose, a seizure, severe confusion or immediate danger should not be managed through a distant admissions inquiry. Medical assessment should precede travel when acute instability is possible. [9]

If medical care and residential treatment take place in different countries, ask how the teams will communicate with consent. The receiving service needs current treatment details, relevant findings and unresolved concerns. The client should understand the plan rather than act as the only messenger between professionals. A booking confirmation does not establish that the clinical handover is complete.

Confirm travel readiness with the responsible clinicians. Leaving a detox unit does not automatically mean every journey or residential setting is suitable immediately. If the recommendation changes, the itinerary should be adaptable. A paid flight or room should not determine medical discharge timing or pressure the person into an unsuitable transition.

Prescribing and medication supply also need clear arrangements. Check the actual route’s requirements through the relevant authorities and clinicians; do not assume a prescription or formulation transfers unchanged across borders. Where ongoing treatment is essential, identify the accepting provider at the destination and after return. A residential plan must not create a gap in appropriate medication care.

COGNIFUL is a residential program in Mallorca, Spain. Its suitability review considers substance use, withdrawal risk, current stability, medical requirements and psychiatric needs. Where medical detoxification, acute care or another specialist service is required, that comes first. COGNIFUL in Mallorca, Spain, offers detoxification as part of its addiction treatment pathway. [4] [8] The medical plan, prescribing responsibilities and any additional specialist support are confirmed individually.

After appropriate medical care, a residential phase may be useful for the therapeutic needs identified in assessment. These can include patterns of use, coping, relationships and preparation for continuing care. Completion of detox is not automatic admission approval. Ask what ongoing needs the residence can support and what must remain with another medical provider.

The residence accommodates a maximum of four clients at any time, each with a private suite. Clinical and bodywork sessions are individual. The residence, chef, personal manager, other holistic sessions, excursions and activities are shared. This describes the living and treatment format; it does not establish hospital facilities, a specific staffing ratio or an outcome advantage. [8]

COGNIFUL Premier and Premier Plus both include assessment, an individual plan and continuing-care planning. Plus adds individual therapeutic work, family and transition work, and three months of aftercare. Follow-up for the base program is agreed individually. Typical stays are four to twelve weeks, individually reviewed; the published fees and stay range describe residential care rather than a medical detox package. [8] View program fees

Ask the written proposal to identify actual clinical work, expected professionals, duration, inclusions and total costs. Separate medical detox, external appointments, medication and travel should be clarified. COGNIFUL is generally self-pay and does not bill insurers directly; reimbursement is not guaranteed. The program choice should be evaluated through the services proposed for the person rather than price alone.

Before discharge, confirm the accepting clinicians and appointments at home. COGNIFUL’s continuing-care planning addresses preparation for ordinary life, while the individual agreement determines follow-up. Do not assume universal cross-border prescribing or remote access to every clinical service. If ongoing medication treatment is needed, its continuity should be explicit. [10]

Ask what each quotation covers. Medical detox may include assessment, monitoring, medication and discharge planning, while a residential quote may cover accommodation and therapeutic work after stabilization. These are different services. A lower total price does not prove better value unless the necessary clinical components and follow-up are comparable.

Ask providers to explain any outcome claims they make. A completion rate, satisfaction survey or short-term abstinence measure does not automatically show the same result as sustained improvement in health and functioning. This guide does not assign a ranking from incomparable claims. The individual decision should focus on the assessed needs, actual service and ability to continue appropriate treatment.

Before choosing residential care, ask what work remains after the medical phase. The answer may concern harmful patterns of use, difficulty responding to distress, disrupted relationships or the practical organization of continuing treatment. Those needs should be described specifically. A person who requires ongoing opioid treatment, for example, needs a residence that can coordinate with that medical plan rather than redefine treatment success as the absence of every medication.

The client should have a role in setting priorities. What would better daily functioning look like? Which situations have repeatedly become difficult? What support has helped in the past? These questions can turn a broad desire for recovery into goals that the treatment team can review. They also make it easier to judge whether a particular program’s proposed work is relevant.

Ask how family participation supports those goals. Relatives may offer useful observations and practical help, but their involvement should follow consent and should not replace professional responsibility. A private setting should make honest communication easier, including the ability to discuss uncertainty or concerns without having to reassure everyone else during treatment.

• Which substance-related problems and medical needs have been identified?
• Who determines the level of care and manages the medical plan?
• How does the approach differ for opioids, benzodiazepines, stimulants or combinations?
• Which ongoing treatment and medication arrangements are confirmed before discharge?
• What must be in place before transfer to a residence or travel home?

Does every drug require the same detox process?

No. The substance, pattern of use, health and treatment goals change the medical pathway. A standard package should not be applied across different drugs without assessment. [1] [2] [3]

Is detox alone appropriate treatment for opioid use disorder?

The CDC advises against detoxification alone and recommends medication treatment because of return-to-use and overdose risks. Ask how appropriate ongoing care is provided or arranged. [1]

Can I stop prescribed sedatives before admission?

Do not make independent changes to prepare for treatment. Abrupt benzodiazepine withdrawal can be dangerous. The responsible clinician should review the actual medicine and determine the plan. [9]

Does COGNIFUL provide onsite drug detox?

COGNIFUL in Mallorca, Spain, offers detoxification as part of its addiction treatment pathway. Medical needs are assessed before admission, and appropriate care may be required elsewhere first. [4]

COGNIFUL admissions can explain residential suitability once necessary medical care is being addressed. Share the actual substances, current treatment and ongoing needs. Acute symptoms or immediate danger require local medical care before a residential booking or international journey. [8] [4]

1. Opioid use disorder: treating — Centers for Disease Control and Prevention.
2. Joint Clinical Practice Guideline on Benzodiazepine Tapering — American Society of Addiction Medicine and partner societies.
3. Clinical Practice Guideline on the Management of Stimulant Use Disorder — American Society of Addiction Medicine and American Academy of Addiction Psychiatry.
4. Clinical scope, suitability and care coordination — COGNIFUL.
5. Psychiatry and Clinical Psychology Department — Clínica Universidad de Navarra.
6. Priory Hospital Roehampton — Priory.
7. Addiction and mental health services in Center City — Hazelden Betty Ford Foundation.
8. COGNIFUL programs, fees, admissions and suitability — COGNIFUL.
9. Benzodiazepine safety communication — US Food and Drug Administration.
10. Reintegration and continuing care — COGNIFUL.

Primary clinical and provider pages accessed October 18, 2026. Individual services, admission and fees should be confirmed directly.